Additional Studies Further Demonstrate Safety and Efficacy of
PuriCore's Vashe(TM) Wound Therapy System
More than 2,000 patients successfully treated including five
with necrotizing fasciitis
MALVERN, PENNSYLVANIA, AND STAFFORD, UK, September 24, 2007-PuriCore (LSE:
PURI), the life sciences company focused on the control of infectious pathogens
with its novel, safe antimicrobial technology, today announced new clinical
results from successful case studies showing the safety and efficacy of its
FDA-cleared Vashe Wound Therapy Solution in a variety of clinical applications.
To date, nine physicians at 13 US clinical sites have used Vashe successfully to
treat more than 2,000 patients with a diverse range of chronic and acute wounds
with no report of adverse effects. The Vashe System produces hypochlorous acid
at near-neutral pH, the same antimicrobial solution produced by the human body
to fight infection.
The clinicians reported positive results and efficacy of Vashe for the treatment
of a variety of challenging wounds including chronic venous ulcers; non-healing
surgical wounds; and necrotizing fasciitis, a rare, life-threatening bacterial
infection of the skin, subcutaneous tissue, and superficial facia with a
mortality rate of 20 to 60%. Five patients suffering from necrotizing fasciitis
were successfully treated with the Vashe Solution.
These and other positive clinical results were presented at the New
Cardiovascular Horizons and Management of the Diabetic Foot & Wound Healing
Conference in New Orleans, LA, September 5-8, and will be presented this week at
Georgetown University Hospital's Diabetic Limb Salvage Conference in Washington,
DC. Previously, studies conducted on patients with chronic venous ulcers at the
University of Oxford in England that were published in the Journal of Wound Care
showed a positive and observable improvement in healing rates and pain reduction
with the use of the Vashe Solution.
"We are very pleased with these promising early clinical results for the Vashe
Solution showing its safety and potential therapeutic value in the management of
such a wide variety of chronic and acute wounds," said Greg Bosch, CEO of
PuriCore.
To date, all clinicians were un-paid, and these studies being conducted are
investigator-driven and non-controlled. PuriCore plans to continue clinical work
to demonstrate the efficacy of Vashe in a broad range of applications, including
initiation of a randomized pilot study focused on post-operative burn
management.
About Vashe
The Vashe Wound Therapy System is a novel, noninvasive, easy-to-use wound
treatment process that has been shown to be complementary to existing treatment
methods. The Vashe System is an FDA-cleared medical device used for moistening,
irrigating, cleaning, and debriding acute and chronic wounds including stage I
through IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical
wounds, first and second degree burns, abrasions, and minor irritations of the
skin. The Vashe Solution mimics the human body's own infection fighter,
hypochlorous acid, to eliminate pathogens that produce harmful toxins and odor
and cause significant pain-all without any tissue damage.
About PuriCore
PuriCore (London Stock Exchange: PURI) is a life sciences company focused on
developing and commercializing proprietary products that safely, effectively,
and naturally kill contagious pathogens. PuriCore's technology provides a
solution to a broad range of markets that depend upon controlling contamination,
including food safety, medical device disinfection, wound therapy, and
hospitality. The Company's proprietary technology mimics the human body's
production of the natural antimicrobial hypochlorous acid, which is highly
effective in killing bacteria, viruses, and fungal spores. Deploying
hypochlorous acid solutions as soaks, sprays, mists, and in other forms,
PuriCore's technology is designed to limit the spread of infectious disease,
including major public health threats of M. tuberculosis, MRSA, E.coli,
norovirus, avian influenza, HIV, polio virus, Helicobater pylori, and
Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in
Stafford, UK.
To receive additional information on PuriCore, please visit our web site at
www.puricore.com, which does not form part of this press release.
Additional Studies Further Demonstrate Safety and Efficacy of PuriCore's Vashe(TM) Wound Therapy System
| Source: PuriCore Plc
Pennsylvania--(Marketwire - September 24, 2007) -